Abstract
Treatment-related acute myeloid leukaemia (t-AML) is a serious complication of topoisomerase 2 inhibitor therapy and is characterised by the presence of mixed lineage leukaemia (MLL) rearrangement. By molecular tracking, we were able to show that MLL cleavage preceded gene rearrangement by 3 months and before the clinical diagnosis of t-AML in a patient with haemophagocytic lymphohistiocytosis. This is the first report on the sequential detection of the two biomarkers in treatment-related leukaemogenesis. © 2004 Cancer Research UK.
Original language | English |
---|---|
Pages (from-to) | 1990-1992 |
Number of pages | 2 |
Journal | British Journal of Cancer |
Volume | 91 |
Issue number | 12 |
Publication status | Published - 13 Dec 2004 |
Keywords
- HLH
- MLL cleavage and rearrangement
- Treatment-related leukaemia